128 related articles for article (PubMed ID: 32365474)
1. Luteinizing Hormone Levels Relate to the Unfavorable Pathology of Prostate Cancer.
Choi SY; Chi BH; Lee W; Lim B; You D; Kim CS
J Clin Med; 2020 Apr; 9(5):. PubMed ID: 32365474
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
[TBL] [Abstract][Full Text] [Related]
3. Influence of radical prostatectomy on serum hormone levels.
Miller LR; Partin AW; Chan DW; Bruzek DJ; Dobs AS; Epstein JI; Walsh PC
J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
[TBL] [Abstract][Full Text] [Related]
4. [Serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone versus prostate specific antigen in patients with localized prostate adenocarcinoma who underwent radical prostatectomy. Radioimmunoassays measurements].
Bantis A; Zissimopoulos A; Athanasiadou P; Gonidi M; Agelonidou E; Strataki A; Matthaios D; Tsartsarakis A
Hell J Nucl Med; 2007; 10(1):56-61. PubMed ID: 17450256
[TBL] [Abstract][Full Text] [Related]
5. Sex hormone-binding globulin is an independent predictor of biochemical recurrence after radical prostatectomy.
Waldert M; Schatzl G; Swietek N; Rom M; Klatte T
J Urol; 2012 Sep; 188(3):792-7. PubMed ID: 22818139
[TBL] [Abstract][Full Text] [Related]
6. Radical prostatectomy: influence on serum and urinary androgen levels.
Olsson M; Ekström L; Schulze J; Kjellman A; Akre O; Rane A; Gustafsson O
Prostate; 2010 Feb; 70(2):200-5. PubMed ID: 19760638
[TBL] [Abstract][Full Text] [Related]
7. Genetic Polymorphism in Sex Hormone-binding Globulin With a Prognosis of Androgen Deprivation Therapy in Metastatic Prostate Cancer Among Japanese Men.
Shiota M; Fujimoto N; Tsukahara S; Ushijima M; Takeuchi A; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Eto M
Clin Genitourin Cancer; 2019 Jun; 17(3):e387-e393. PubMed ID: 31036465
[TBL] [Abstract][Full Text] [Related]
8. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
9. Reference intervals for important serum sex steroid hormones, prostate-specific antigen, insulin-like growth factor-1 and IGF binding protein-3 concentration in a normal Kuwaiti adult male population.
Kehinde EO; Akanji AO; Mojiminiyi OA; Al-Awadi KA; Al-Hunayan A; Bashir AA; Abraham MP
Med Princ Pract; 2005; 14(5):342-8. PubMed ID: 16103701
[TBL] [Abstract][Full Text] [Related]
10. Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer.
Planas J; Celma A; Placer J; Cuadras M; Regis L; Gasanz C; Trilla E; Salvador C; Lorente D; Morote J
Scand J Urol; 2016 Dec; 50(6):425-428. PubMed ID: 27628623
[TBL] [Abstract][Full Text] [Related]
11. Are higher follicle-stimulating hormone levels before androgen deprivation therapy for prostate cancer associated with oncological and cardiac outcomes and overall survival?-a population-level analysis.
Dymanus K; Friedrich NA; Howard LE; Oyekunle T; De Hoedt AM; Labadzhyan A; Polascik T; Klaassen Z; Freedland SJ
Transl Androl Urol; 2023 Oct; 12(10):1540-1549. PubMed ID: 37969776
[TBL] [Abstract][Full Text] [Related]
12. Investigative clinical study on prostate cancer part VI: Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population.
Porcaro AB; Migliorini F; Petrozziello A; Sava T; Romano M; Caruso B; Cocco C; Ghimenton C; Zecchinini Antoniolli S; Lacola V; Rubilotta E; Monaco C; Comunale L
Urol Int; 2012; 88(2):150-7. PubMed ID: 22205171
[TBL] [Abstract][Full Text] [Related]
13. Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer.
Hoare D; Skinner TA; Black A; Robert Siemens D
Can Urol Assoc J; 2015; 9(3-4):122-7. PubMed ID: 26085869
[TBL] [Abstract][Full Text] [Related]
14. [Changes of sex hormones and sex hormone-binding globulin levels in male adults with hyperthyroidism before and after antithyroid drug treatment].
Ma WL; Wang X; Mao JF; Cheng XQ; Nie M; Liu ZX; Zheng JJ; Yu BQ; Hao M; Huang QB; Zhang R; Gao YJ; Wu XY
Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1875-1880. PubMed ID: 31269583
[No Abstract] [Full Text] [Related]
15. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
16. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
17. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
[TBL] [Abstract][Full Text] [Related]
18. The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy.
Heracek J; Urban M; Sachova J; Kuncova J; Eis V; Mandys V; Hampl R; Starka L
Neuro Endocrinol Lett; 2007 Feb; 28(1):45-51. PubMed ID: 17277727
[TBL] [Abstract][Full Text] [Related]
19. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
[TBL] [Abstract][Full Text] [Related]
20. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
Platz EA; Leitzmann MF; Rifai N; Kantoff PW; Chen YC; Stampfer MJ; Willett WC; Giovannucci E
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1262-9. PubMed ID: 15894683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
